Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Stock Statistics & Valuation Metrics

Hangzhou Tigermed Consulting Co., Ltd. Class H has a market cap or net worth of EUR 5.02B. The enterprise value is EUR 43.47B.

Market Cap

EUR 5.02B

Enterprise Value

EUR 43.47B

Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

123,124,800

Owned by Insiders

―

Owned by Institutions

15.43%

Hangzhou Tigermed Consulting Co., Ltd. Class H’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.11%.

Return on Equity (ROE)

0.04

Return on Assets (ROA)

0.03

Return on Invested Capital (ROIC)

3.11%

Return on Capital Employed (ROCE)

0.04

Revenue Per Employee

613.91K

Profits Per Employee

79.77K

Employee Count

11,130

Asset Turnover

0.24

Inventory Turnover

119.50

The current PE Ratio of Hangzhou Tigermed Consulting Co., Ltd. Class H is -101.90. Hangzhou Tigermed Consulting Co., Ltd. Class H’s PEG ratio is 0.60.

PE Ratio

-101.90

PS Ratio

4.71

PB Ratio

2.08

Price to FCF

32.26

Price to Operating Cash Flow

31.83

PEG Ratio

0.60

In the last 12 months, Hangzhou Tigermed Consulting Co., Ltd. Class H had revenue of 6.83B and earned 887.89M in profits. Earnings per share was 1.03.

Revenue

6.83B

Gross Profit

1.87B

Operating Income

1.01B

Pretax Income

1.00B

Net Income

887.89M

EBITDA

1.42B

Earnings Per Share (EPS)

1.03

In the last 12 months, operating cash flow was 1.29B and capital expenditures -172.68M, giving a free cash flow of 1.12B billion.

Operating Cash Flow

1.29B

Free Cash Flow

1.12B

Free Cash Flow per Share

1.33

Hangzhou Tigermed Consulting Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of 0.36%

Dividend Per Share

―

Dividend Yield

0.36%

Payout Ratio

N/A

Free Cash Flow Yield

3.10%

Earnings Yield

-0.99%

Beta

0.61

52-Week Price Change

-13.25%

50-Day Moving Average

4.65

200-Day Moving Average

4.35

Relative Strength Index (RSI)

44.82

Average Volume (3m)

7

Hangzhou Tigermed Consulting Co., Ltd. Class H upcoming earnings date is Mar 29, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 29, 2026

Next Earnings Date

Mar 29, 2027

Ex-Dividend Date

―

Hangzhou Tigermed Consulting Co., Ltd. Class H as a current ratio of 2.18, with Debt / Equity ratio of 7.04%

Current Ratio

2.18

Quick Ratio

2.16

Debt to Market Cap

0.03

Net Debt to EBITDA

-0.21

Interest Coverage Ratio

11.15

In the past 12 months, Hangzhou Tigermed Consulting Co., Ltd. Class H has paid 198.16M in taxes.

Income Tax

198.16M

Effective Tax Rate

0.20

Hangzhou Tigermed Consulting Co., Ltd. Class H EV to EBITDA ratio is 24.16, with an EV/FCF ratio of 32.25.

EV to Sales

4.71

EV to EBITDA

24.16

EV to Free Cash Flow

32.25

EV to Operating Cash Flow

27.93

Hangzhou Tigermed Consulting Co., Ltd. Class H has EUR 2.12B in cash and marketable securities with EUR 2.10B in debt, giving a net cash position of EUR 21.82M billion.

Cash & Marketable Securities

EUR 2.12B

Total Debt

EUR 2.10B

Net Cash

EUR 21.82M

Net Cash Per Share

EUR 0.18

Tangible Book Value Per Share

EUR 23.62

Gross margin is 25.80%, with operating margin of 8.58%, and net profit margin of -5.32%.

Gross Margin

25.80%

Operating Margin

8.58%

Pretax Margin

-2.76%

Net Profit Margin

-5.32%

EBITDA Margin

19.50%

EBIT Margin

15.90%

The average price target for Hangzhou Tigermed Consulting Co., Ltd. Class H is EUR 5.71, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

EUR 5.71

Price Target Upside

32.09% Upside

Analyst Consensus

Moderate Buy

Analyst Count

3

Revenue Growth Forecast

15.61%

EPS Growth Forecast

-171.58%

Smart Score

7

AI Score

―